Evaluation of The Cost Saving Potential of Introducing Benepali®, An Etanercept Biosimilar, For The Treatment of All Licensed Adult Etanercept Indications In Three Regions In Italy
Abstract
Authors
E Psachoulia C Negrini
E Psachoulia C Negrini
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now